Efficacy of Alternative Antiandrogens to Treat Advanced Prostate Cancer That Relapsed after Initial Hormone Therapy

Jian-ping WU,Hong-bin SUN,Jia-geng ZHU,Jiang-hao SU,Zheng XU,Lu-wei XU,Quan-liang DOU,Rui-peng JIA

DOI: https://doi.org/10.3969/j.issn.1674-7410.2014.04.003

2014-01-01

Abstract:Objective To evaluate the efficacy of second-line hormone therapy with flutamide in patients who relapsed after initial maximum androgen blockade (MAB). Methods 48 patients were treated with MAB u-sing flutamide (375 mg daily)as second-line hormonal therapy. All patients were initially treated with first-line MAB consisting of either medical or surgical castration plus bicalutamide,which failed. The effect of second-line MAB was evaluated by the serum PSA level,and the response was divided into >50% and <50% PSA reductions from baseline PSA at the start of second-line hormonal therapy. Results PSA reduction was observed in 29 patients (60. 4%). Among them,17 (35. 4%)achieved >50% PSA reductions with a mean response duration of (10. 2 ± 3. 5)months. 12 (25. 0%)patients achieved <50% PSA reductions with a mean response duration of (7. 4 ± 2. 7)months. Patients with long-time response duration of first-line MAB had a signifi-cantly higher incidence of PSA response to second-line therapy,other factors such as age,Gleason score,ser-um PSA before the start of first-line or second-line hormonal therapy,nadir PSA level after first-line or sec-ond-line hormonal therapy were not correlated to the response of second-line therapy. Conclusions Second-line MAB using flutamide is suitable for patients who relapse after initial MAB therapy using bicalutamide,par-ticularly in those with long-time response duration of first-line MAB,and may be an effective treatment option before cytotoxic chemotherapy.